Ishita Drugs & Industries Ltd Schedules Board Meeting on February 07, 2026 for Q3FY26 Financial Results

1 min read Updated on 30 Jan 2026, 04:04 PM

Reviewed by

Naman SScanX News Team

Overview

Ishita Drugs & Industries Ltd has scheduled a board meeting for February 07, 2026, to approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025. The meeting complies with SEBI Regulation 29 requirements. A trading window closure is in effect from January 1, 2026, until 48 hours after results announcement, following insider trading prevention protocols.

*this image is generated using AI for illustrative purposes only.

Ishita drugs & indus has formally notified the BSE about an upcoming board meeting to review its quarterly financial performance. The pharmaceutical company will convene its board of directors on February 07, 2026, to deliberate on crucial financial matters for the third quarter of fiscal year 2026.

Meeting Agenda and Regulatory Compliance

The board meeting has been scheduled in strict adherence to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda includes consideration, approval, and recording of the company's unaudited financial results for the quarter ended December 31, 2025.

Meeting Details:	Information
Date:	Saturday, February 07, 2026
Primary Agenda:	Unaudited Financial Results for Q3FY26
Quarter Period:	October 1 - December 31, 2025
Regulatory Framework:	SEBI Regulation 29

Trading Window Restrictions

In compliance with insider trading prevention protocols, Ishita Drugs & Industries Ltd has implemented a trading window closure for designated persons. This restriction became effective from Thursday, January 1, 2026, and will continue until 48 hours following the official announcement of the unaudited financial results.

The trading window closure aligns with the company's Code of Conduct for Prevention of Insider Trading, which has been framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015. This measure ensures fair market practices and prevents any potential misuse of unpublished price-sensitive information.

Corporate Communication

The official notification was signed by Jagdish Agrawal, Managing Director of Ishita Drugs & Industries Ltd, and submitted to the BSE Limited on January 30, 2026. The company maintains its corporate office at C. G. Road, Ahmedabad, with its registered office and manufacturing facility located in Vasna-Iyava, Sanand, Ahmedabad district.

Company Background

Ishita Drugs & Industries Ltd operates under the corporate identification number L24231GJ1992PLC017054 and trades on BSE with scrip code 524400. The company positions itself with the mission statement "Our basic drugs in the service of humanity worldwide," reflecting its commitment to pharmaceutical manufacturing and healthcare solutions.

Historical Stock Returns for Ishita Drugs & Indus

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-100.00%	-100.00%	-100.00%	-100.00%	-100.00%	-100.00%

Ishita Drugs & Indus

View Company Insights

View All News

Ishita Drugs & Industries Promoter Jagdish Agrawal Acquires Additional 254 Shares

1 min read Updated on 31 Dec 2025, 04:28 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Overview

Jagdish Agrawal, promoter of Ishita Drugs & Industries Ltd, acquired 254 equity shares worth ₹2,540 through open market transactions on December 29, 2025. His shareholding increased marginally from 4.40% to 4.41%, with total holding rising from 131,555 to 131,809 shares. The acquisition was disclosed to BSE Limited on December 30, 2025, in compliance with SEBI regulations. The company's equity share capital remains stable at ₹2.99 crores comprising 2,990,300 shares of ₹10 each.

*this image is generated using AI for illustrative purposes only.

Jagdish Agrawal, a promoter of Ishita Drugs & Industries Ltd , has acquired additional equity shares in the pharmaceutical company through open market transactions. The acquisition was formally disclosed to BSE Limited on December 30, 2025, in compliance with SEBI regulations governing substantial acquisition of shares.

Transaction Details

The share acquisition transaction involved specific parameters that demonstrate the promoter's continued investment in the company:

Parameter:	Details
Shares Acquired:	254 equity shares
Face Value:	₹10.00 per share
Transaction Value:	₹2,540.00
Acquisition Date:	December 29, 2025
Mode of Acquisition:	Open Market

Shareholding Pattern Changes

The acquisition resulted in a marginal increase in Agrawal's ownership stake in the company. The following table illustrates the changes in his shareholding pattern:

Holding Period:	Number of Shares	Percentage of Total Capital
Before Acquisition:	131,555 shares	4.40%
Shares Acquired:	254 shares	0.01%
After Acquisition:	131,809 shares	4.41%

The transaction represents a minimal increase in the promoter's stake, with the percentage holding rising by just 0.01 percentage points.

Company Capital Structure

Ishita Drugs & Industries Ltd maintains a stable capital structure following this transaction. The company's equity share capital remained unchanged at ₹2.99 crores, consisting of 2,990,300 equity shares with a face value of ₹10.00 each. The total diluted share capital also remains at the same level, indicating no outstanding convertible securities or warrants.

Regulatory Compliance

The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Agrawal, identified as a promoter of the company, fulfilled the mandatory reporting requirements by submitting the necessary documentation to BSE Limited within the prescribed timeframe. The company's shares are listed on BSE Limited under scrip code 524400.

Historical Stock Returns for Ishita Drugs & Indus